Timothy O'Donnell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7156801/publications.pdf

Version: 2024-02-01

24 papers

1,462 citations

933447 10 h-index 14 g-index

29 all docs

29 docs citations

29 times ranked 3254 citing authors

#	Article	IF	CITATIONS
1	Landscape and selection of vaccine epitopes in SARS-CoV-2. Genome Medicine, 2021, 13, 101.	8.2	30
2	TGM4: an immunogenic prostate-restricted antigen. , 2021, 9, e001649.		11
3	Repeat elements amplify TLR signaling. Nature Reviews Immunology, 2021, 21, 760-760.	22.7	5
4	82â€Single-cell RNA sequencing and CITE-Seq analysis of bladder cancer patient urine with matched tumor and peripheral blood suggests urine as a window into the tumor immune microenvironment. , 2021, 9, A90-A90.		0
5	Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell, 2020, 183, 982-995.e14.	28.9	440
6	A Comprehensive Phenotypic and Functional Immune Analysis Unravels Circulating Anti–Phospholipase A2 Receptor Antibody Secreting Cells in Membranous Nephropathy Patients. Kidney International Reports, 2020, 5, 1764-1776.	0.8	26
7	Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors. Cell, 2020, 183, 1634-1649.e17.	28.9	103
8	MHCflurry 2.0: Improved Pan-Allele Prediction of MHC Class I-Presented Peptides by Incorporating Antigen Processing. Cell Systems, 2020, 11, 42-48.e7.	6.2	172
9	High-Throughput MHC I Ligand Prediction Using MHCflurry. Methods in Molecular Biology, 2020, 2120, 113-127.	0.9	4
10	168â€A novel prostate-restricted tumor-associated antigen: a potential therapeutic target. , 2020, , .		O
11	478â€Translation of a therapeutic neoantigen vaccine workflow to SARS-CoV-2 vaccine development. , 2020, , .		O
12	289â€PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting. , 2020, , .		O
13	Bioinformatic methods for cancer neoantigen prediction. Progress in Molecular Biology and Translational Science, 2019, 164, 25-60.	1.7	27
14	Abstract A005: A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers. , 2019 , , .		0
15	Abstract B032: PhIP-seq assessment of the serum antibody repertoire before and after immune-related adverse events in four melanoma patients treated with checkpoint blockade immunotherapy., 2019,,.		O
16	A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies Journal of Clinical Oncology, 2019, 37, e14307-e14307.	1.6	2
17	MHCflurry: Open-Source Class I MHC Binding Affinity Prediction. Cell Systems, 2018, 7, 129-132.e4.	6.2	311
18	Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer. BMC Cancer, 2018, 18, 87.	2.6	33

#	Article	IF	CITATIONS
19	Estimating Local Costs Associated With (i) Clostridium difficile (i) Infection Using Machine Learning and Electronic Medical Records. Infection Control and Hospital Epidemiology, 2017, 38, 1478-1486.	1.8	7
20	Estimating Local Attributable Cost of Clostridium difficile Infection Using Electronic Medical Record Data. Open Forum Infectious Diseases, $2016, 3, .$	0.9	0
21	Abstract A022: Computational pipeline for a personalized genomic vaccine trial., 2016,,.		O
22	Key mutations stabilize antigenâ€binding conformation during affinity maturation of a broadly neutralizing influenza antibody lineage. Proteins: Structure, Function and Bioinformatics, 2015, 83, 771-780.	2.6	34
23	Automated Identification of Emerging Drug Resistance by Retrospective Mining of Electronic Medical Records. Open Forum Infectious Diseases, 2015, 2, .	0.9	0
24	Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 264-269.	7.1	227